Kairos Seeks Vote to Lift Equity Plan to 20M Shares, Shield Pool From Reverse Splits
KAPA is trading near its 52-week low of $0.381 (6.8% above the low) on light trading volume (0.1× avg).
Summary
Kairos filed a preliminary proxy for a special meeting asking holders to expand its 2023 Equity Incentive Plan to 20,000,000 shares and to stop reverse splits from cutting the authorized pool. The change would enlarge future equity dilution, especially after any reverse split.
Key Events · Corporate Governance and Compliance · KAPA
-
Plan Reserve Raised to 20 Million Shares
On 2026-11-19 the Board approved, subject to stockholder approval, raising the maximum shares available under the 2023 Equity Incentive Plan to 20,000,000, up from the 1,650,000 originally reserved in July 2023 plus the 5,000,000 added in June 2026.
-
Reverse Split No Longer Cuts Plan Pool
Section 13 would be revised so a reverse split adjusts outstanding awards and their exercise prices but does not proportionately reduce authorized shares, leaving a larger pool relative to the post-split share count.
-
Dilution Risk Explicitly Flagged
The proxy states that after a reverse split the remaining available shares would represent a greater percentage of outstanding common stock than before, and future issuances could have a greater dilutive effect on stockholders.
-
Special Meeting Called, Date Left Blank
A virtual special meeting will be held on a date shown as [*], 2026, with the record date also blank; the Board unanimously recommends voting FOR the Plan Amendment.
Analysis · KAPA · Life Sciences
Shareholders are being asked to raise the 2023 Equity Incentive Plan reserve to 20,000,000 shares and to amend Section 13 so a reverse split shrinks outstanding awards but leaves the authorized pool intact. That second change carries the most weight: after a reverse split, an untouched pool would represent a much larger slice of the smaller share count, so future grants would dilute more than they do today. Kairos says it lacks enough shares for planned compensation and would otherwise have to pay more in cash — cash it does not have, given the $3.1 million balance and going-concern warning reported in the 10-Q filed 2026-11-13. Approval also satisfies NYSE American equity-plan voting rules and preserves ISO tax treatment.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KAPA was trading at $0.41 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $0.38 to $7.28. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.